- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
Neuronetics Announces Chief Financial Officer Transition
Reaffirms Fiscal Year 2026 Financial Guidance
Apr. 7, 2026 at 7:07am
Got story updates? Submit your updates here. ›
A premium medical device from Neuronetics, a leader in innovative mental health treatments, stands elegantly in a minimalist studio setting.Malvern TodayNeuronetics, Inc., a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company. The Company has launched a search to identify Mr. Pfanstiel's replacement.
Why it matters
This transition in the CFO role at Neuronetics comes as the company continues to focus on expanding its NeuroStar Advanced Therapy System, a non-drug, noninvasive treatment for major depressive disorder and other mental health conditions. The departure of the CFO is not due to any dispute or disagreement, and the company has reaffirmed its fiscal year 2026 financial guidance.
The details
Steven E. Pfanstiel will remain with Neuronetics through May 1, 2026 to support an orderly transition. The company has launched a search to identify his replacement. In conjunction with the announcement, Neuronetics reaffirmed the financial guidance it provided during its fourth quarter 2025 earnings call on March 17, 2026.
- Pfanstiel will depart his role on May 1, 2026.
- Neuronetics provided its fourth quarter 2025 earnings guidance on March 17, 2026.
The players
Neuronetics, Inc.
A medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, and the maker of the NeuroStar Advanced Therapy System.
Steven E. Pfanstiel
The departing Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, who is leaving to pursue an opportunity outside the company.
The takeaway
This transition in the CFO role at Neuronetics comes as the company continues to focus on expanding its NeuroStar Advanced Therapy System, a non-drug, noninvasive treatment for major depressive disorder and other mental health conditions. The departure of the CFO is not due to any dispute or disagreement, and the company has reaffirmed its fiscal year 2026 financial guidance, signaling stability and confidence in the business during this leadership change.
